Curriculum Vitae

* ******* ****

Doylestown, PA 18901

Cell: 267-***-****

Martin Otto Behm, MD

EDUCATION

Fellowship Training Program:

Pediatric Clinical Pharmacology

The Children’s Mercy Hospital

2401 Gillham Road

Kansas City, MO

July 2001 – June 2004

Pediatric Residency Training Program:

New York University Hospital/Bellevue Hospital

New York, NY

June 1998 – June 2001

Medical School:

Georgetown University School of Medicine

Washington, DC

August 1994 – May 1998

Undergraduate Education: Marquette University

Milwaukee, WI

Honors Bachelor of Science Degree Cum Laude

Majors: Biochemistry and Theology

August 1990 – May 1994

High School:

St. Louis University High School

St. Louis, MO

August 1986-May 1990

LICENSURE/CERTIFICATION

Missouri State Board of Registration for the Healing Arts Physician

EMPLOYMENT

Merck & Co.

351 N. Sumneytown Pike

North Wales, PA 19454

Senior Director

Transformation Pharmacology

July 2006-Present

Responsible for the development and execution of clinical pharmacology development programs for prescription company products. Evaluates possible safety signals for drugs in early development as well as in post marketed drugs. Responsible for study design, protocol development and execution of clinical studies. Acts as a liaison between company and clinical investigators. Develops credible relationships with opinion leaders, medical directors and key regulatory officials. Responsible for medical monitoring/reporting activities. Evaluates adverse events of drugs in clinical studies for relationship to treatment. Acts as medical contact at company for the FDA concerning clinical/medical issues. Interprets, reports and prepares oral and written results of product research in preparation for FDA submissions. Assists Regulatory Affairs in the development of drug regulatory strategies. Acts as company spokesperson regarding publication of clinical research findings and presentations to relevant FDA advisory committees. Helps explore and evaluate new product ideas to assist in identifying new marketing opportunities. Supports general clinical activities involving product evaluation, labeling and surveillance. Participate on cross- functional teams for evaluation of new product ideas, implement franchise business strategies, etc. Reviews medical literature and related new technologies. Responsible for assessment of external clinical research proposals involving company products relevant to company’s mission.

McNeil Consumer and Specialty Pharmaceutics

7050 Camp Hill Road

Fort Washington, PA 19440

Associate Director Drug Development and Safety

May 2005-June 2006

Responsible for the development and execution of clinical development programs for prescription company products in all phases of clinical development (Phase 1-4). Responsible for study design, protocol development and execution of clinical studies. Acts as a liaison between company and

clinical investigators. Develops credible relationships with opinion leaders, medical directors and key regulatory officials. Responsible for medical monitoring/reporting activities. Evaluates adverse events of drugs in clinical studies for relationship to treatment. Acts as medical contact at company for the FDA concerning clinical/medical issues. Interprets, reports and prepares oral and written results of product research in preparation for FDA submissions. Assists Regulatory Affairs in the development of drug regulatory strategies. Acts as company spokesperson regarding publication of clinical research findings and presentations to relevant FDA advisory committees. Helps explore and evaluate new product ideas to assist in identifying new marketing opportunities. Supports general Clinical activities involving product evaluation, labeling and surveillance. Participate on cross-functional teams for evaluation of new product ideas, implement franchise business strategies, etc. Reviews medical literature and related new technologies. Responsible for assessment of external clinical research proposals involving company products relevant to company’s mission.

PRA International, Inc.

16300 College Boulevard

Lenexa, Kansas 66219

Director of Pediatric Early Development Services & Pediatric Clinical

Pharmacology

January 2004-May 2005

Serves as Director of PRA International’s Early Development Services. Oversees a group of Pediatric research specialists including: Pediatric nursing, Pediatric Nutrition, Pediatric Respiratory Therapy, Child Life, Pediatric Recruiting, and Pediatric Pharmacology. Provides therapeutic and scientific leadership in all steps of Pediatric clinical trials from: protocol design and development, consent writing, dose formulation, IRB approval, recruiting, PK/PD analysis, pharmacogenomic/pharmacogenetic analysis, drug-drug and drug-complementary medicine analysis, data management and analysis, as well as final publications. Serves as Principal Investigator for Pediatric clinical research trials. Serves as Pediatrician for study specific and age-appropriate: history/physical examinations, assessment of subject qualifications for entry into studies, and interpretation of Pediatric medical procedures (e.g., ECGs, PFTs, radiographs, clinical laboratory tests). Directs staff education and training for Pediatric trials including, but not limited to, Wednesday afternoon Pediatric staff lecture series.

Phase I Unit Research Physician

January 2004 – May 2005

Serves as a Principal Investigator for clinical research trials. Overseeing study conduct and guiding procedural study management in adherence of study

protocol and GCP guidelines. Involvement in budgetary planning. Interaction with Institutional Review Boards. Study specific history/physical examinations, assessment of subject qualifications for entry into studies including adherence of inclusion/exclusion criteria, interpretation of medical procedures (e.g. ECGs, PFTs, radiographs, clinical laboratory tests, etc.) and any other pre-dose requirement. Presence at initial dosing, follow-up subject care and any adverse event evaluation, management or coding. Contact with sponsor’s medical directors concerning study drug development history, study goals, management and outcome. Participation in training and education of personnel as it applies to study-specific medical and safety procedures in addition to ongoing applicable GCP education. Attendance at Investigator meetings or sight visits, medical review of research proposals, strategic development participation, and interaction in client relationships.

Children’s Mercy Hospital

2401 Gillham Road

Kansas City, MO 64111

Pediatric Urgent Care Center Physician

February 2003- May 2005

Serves as Pediatric Physician in an urgent care center at Children’s Mercy Hospital. Evaluation and treatment of neonates to 18 year olds. Interpretation of medical procedures e.g., radiographs, and laboratory results.

PROFESSIONAL AFFILIATIONS American Academy of Pediatrics

American Society of Clinical Pharmacology and Therapeutics

AWARDS AND OTHER PROFESSIONAL ACTIVITIES

2003 Presidential Trainee Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT) in recognition of quality of research present (Impact of Ontogeny on Phase II Enzyme Activity

1993 Alpha Sigma Nu (Jesuit Honors Society)

1990 Alpha Epsilon Delta (Premedical Society)

PRIOR NIH SUPPORT

3 U01 HD31312-10S1 (G.L. Kearns, PharmD, PhD-PI; M.O. Behm, M.D.-Project Director) Period of Award: 09/30/02-12/32/03 70%/20% Effort on Project (Drs. Behm/Kearns) NICHD (NIH Director’s PPRU supplemental funding initiative of 2002) Peer-reviewed, competitive supplement to PPRU Cooperative Agreement $115,963 (total Direct costs) Major goals were to support PPRU protocol #10608 (Ontogeny of Phase II Enzymes); an investigator-initiated translational science study designed to characterize the impact of ontogeny on important SULT and UGT isoforms during the first year of life using a combined pharmacokinetic and pharmacogenetic approach.

1F32 HD043529-01 (M.O. Behm, M.D.-PI; G.L. Kearns Pharm.D., Ph.D-Research Mentor) Proposed Period of Award: 01/01/03-12/31/04 100% Salary Support (Dr. Behm) NICHD (priority score=153; NICHD Council funding cut-off score from 09/02 meeting-181). Peer-reviewed Individual NRSA Application to support postdoctoral training in Clinical Pharmacology. Major goals were to complete a 3 year postdoctoral fellowship in pediatric clinical pharmacology with a major (i.e., 75-80%) emphasis on research (clinical, basic and translational). Award primarily provided salary/benefit support for Dr. Behm to conduct an investigator-initiated study on the ontogeny of important phase II drug metabolizing enzymes that was supported by a supplement to the Pediatric Research Unit cooperative agreement (3 U01 HD31313-10S1).

PUBLICATIONS

Behm MO, Kearns GL. Treatment of pain with gabapentin in a neonate. Pediatrics.

2001 Aug;108(2):482-4.

Behm MO, Abdel-Rahman SM, Leeder SJ, Kearns GL. Ontogeny of Phase II Enzymes. Clin Pharmacol Ther. 2003 Feb;73(2) P29.

Behm MO, Kearns GL. Crotaline Fab antivenom for treatment of children with rattlesnake envenomation. Pediatrics. 2003 Dec;112(6 Pt 1):1458-9.

Behm MO, Lennartz P., and Mulberg A.E. Investigation on the behavior of Pancrelipase microtablets (Pancrease® MT), enteric-coated, dispersed in formula (Abstract). Clin Pharmacol Ther. 2006 Feb: 79 (2) P70.

Behm MO; Blanchard R.L; Murphy M.G; Chodakewitz J.A.;Palcza J.S.; Harris D.E.; Butterfield K.L.; Smith W.B.; Haynes E.M.; Sackner-Bernstein J.; Preston R.A.; Krucoff M.W. Assessment of the Effect of MK-0974, an Oral CGRP Receptor Antagonist, on Spontaneous Ischemia in Patients with Stable Cardiovascular Disease. Headache: The Journal of Head and Face Pain. 2008 May; 48 (S1): S39.

Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, Katz DA, Milton MN, Murray BP, Polli JW, Ricci D, Shipley LA, Vangala S, Wrighton SA. PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol. 2008 Jul;48(7):849-89.

Behm MO. (Jan 2009). "Developmental Hepatic Pharmacology in Pediatrics" in Pediatric Drug Development: Concepts and Applications. Edited by Mulberg AE, Silber SA, and van den Anker, JN. Wiley-Blackwell.

Han TH, Blanchard RL, Palcza JS, Behm MO, Wilson K, Xu Y, Ermlich S, Gutierrez M, Hwang E, Miller-Stein CM, Panebianco D, Rippley RK, Murphy MG. Lack of effect of age and gender on the single dose pharmacokinetics of telcagepant, a novel calcitonin gene related peptide (CGRP) receptor antagonist, in healthy subjects. Submitted Clin Pharmacol Ther.

DE HOON, J.N., MACLEOD, C., PALCZA, J.S., BEHM, M.O., DE LEPELEIRE, I., HAN, T.H., PANEBIANCO, D.L., SMITH, W.B., NOONAN, G.P., BLANCHARD, R.L.*, CHODAKEWITZ, J.A., MURPHY, M.G. Lack of significant drug-drug interaction between telcagepant 600 mg and sumitriptan 100 mg. For presentation at: American Headache Society 14th International Headache Biennial Congress, Philadelphia, Pennsylvania, 9/10/09 - 9/13/09.

BEHM, M.O.*, DINGEMANSE, J., NICOLAS, L., HARRIS, D.E., TAYLOR, A.B., TREIBER, A., DENNEY, W.S., PANEBIANCO, D.L., HWANG, E., SMITH, W.B., MURPHY, M.G. A drug-drug interaction study of mk-8141/act-077825/ co- administered with midazolam to evaluate concurrent cyp3a4 induction and inhibition potential. For presentation at: American College Of Clinical Pharmacology 38th Annual Meeting (accp), San Antonio, Texas, 9/13/09 - 9/15/09.

NICOLAS, L., BINKERT, C., MANT, T., BEHM, M.O.*, DINGEMANSE, J. Integrated clinical pharmacology of single and multiple ascending doses of act-

178882/mk-1597, a new renin inhibitor. For presentation at: American College Of

Clinical Pharmacology 38th Annual Meeting (accp), San Antonio, Texas, 9/13/09 -

9/15/09.

NICOLAS, L., BINKERT, C., JUNGNIK, A., BEHM, M.O.*, DINGEMANSE, J. Clinical pharmacology of multiple ascending doses of act-077825/mk-8141, a new renin inhibitor. For presentation at: American College Of Clinical Pharmacology 38th Annual Meeting (accp), San Antonio, Texas, 9/13/09 - 9/15/09.

CHAITMAN, B., HO, A.P., BEHM, M.O., ROWE, J.F., PALCZA, J.S., LAETHEM, T., HEIRMAN, I., PANEBIANCO, D.L., HO, T.W., CHODAKEWITZ, J.A., MURPHY, M.G., BLANCHARD, R.L.* Telcagepant, a cgrp receptor antagonist, has no effect on treadmill-induced exercise tolerance in patients with stable angina. For presentation at: American Heart Association 82nd Annual Meeting, Orlando, Florida,

11/14/09 - 11/18/09.

Behm MO, Blanchard RL, Murphy MG, Palcza JS, Harris DE, Butterfield KL, Smith WB, Preston RA, Chodakewitz JA, Krucoff MW. Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study.

Van de Vijver E, Desager K, Mulberg AE, Staelens S, Verkade HJ, Bodewes FA, Malfroot A, Hauser B, Sinaasappel M, Van Biervliet S, Behm M, Pelckmans P, Callens D, Veereman-Wauters G. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):61-4.

Chaitman BR, Ho AP, Behm MO, Rowe JF, Palcza JS, Laethem T, Heirman I, Panebianco DL, Kobalava Z, Martsevich SY, Free AL, Bittar N, Chrysant SG, Ho TW, Chodakewitz JA, Murphy MG, Blanchard RL. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012 Mar;91(3):459-66.

Behm MO. (Jan 2013). "Developmental Hepatic Pharmacology in Pediatrics" in Pediatric Drug Development: Concepts and Applications-Second Edition. Edited by Mulberg AE, Dianne Murphy, Julia Dunne, Lisa Mathis. Wiley-Blackwell.

Behm MO, Kosoglou T, Miltenburg AM, Li J, Statkevich P, Johnson-Levonas AO, Martinho M, Fackler P. The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2013 Oct;2(4):310-5

Depré M, Macleod C, Palcza J, Behm MO, de Lepeleire I, Han T, Panebianco D, Smith W, Blanchard R, Chodakewitz J, Murphy M, de Hoon J. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine. Cephalalgia. 2013 Dec;33(16):1292-301.

Vargo R, Adewale A, Behm MO, Mandema J, Kerbusch T. Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses. Clin Pharmacol Ther. 2014 Jul;96(1):101-9.

LANGUAGES

English

NATIONALITY

United States

References

Available on Request

Contact this candidate